Literature DB >> 19622879

Systemic Inflammatory Response Syndrome and postoperative complications after orthognathic surgery.

Kiyohiro Kasahara1, Yasutomo Yajima, Chihaya Ikeda, Isao Kamiyama, Takashi Takaki, Takashi Kakizawa, Takahiko Shibahara.   

Abstract

Symptoms of Systemic Inflammatory Response Syndrome (SIRS) presenting immediately after surgery have lately been regarded as potential warnings of impending postoperative complications and multiple organ failure. Reports discussing the relationship between operative stress and SIRS are found in the field of digestive surgery, but not in that of oral surgery. Sixty-five patients with jaw deformity who had undergone maxillary and mandibular orthognathic surgery (Le Fort I osteotomy and sagittal splitting ramus osteotomy) between September 2003 and October 2006 were involved in this study. A search based on the SIRS diagnostic criteria resulted in assignment of 33 cases to the SIRS group and 32 cases to the non-SIRS group. Postoperative complications occurred in 27.3% of the SIRS group and 0.0% of the non-SIRS group (p<0.01). In four cases, a postoperative fluctuation in IL-6 level evaluated. These results suggest the importance of careful management of postoperative SIRS patients in preventing complications.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19622879     DOI: 10.2209/tdcpublication.50.41

Source DB:  PubMed          Journal:  Bull Tokyo Dent Coll        ISSN: 0040-8891


  2 in total

1.  Prevalence of the systemic inflammatory response syndrome in patients who underwent orthognathic surgery.

Authors:  Magno Liberato Silva; Andréia Ferreira Ribeiro; Fábio Ricardo Loureiro Sato; Roger William Fernandes Moreira
Journal:  Oral Maxillofac Surg       Date:  2018-04-11

2.  Upregulation of TLR2/4 expression in mononuclear cells in postoperative systemic inflammatory response syndrome after liver transplantation.

Authors:  Ziqing Hei; Xinjin Chi; Nan Cheng; Gangjian Luo; Shangrong Li
Journal:  Mediators Inflamm       Date:  2010-06-16       Impact factor: 4.711

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.